GANX 8-K: SEC filing

Gain Therapeutics

Filed with the SEC on · accession 0001104659-26-129142

GANX filed a 8-K (current report) with the SEC on Nov 17, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved +25.0% by the first close after the filing.

Summary of the filing

Gain Therapeutics announced positive 12-month Phase 1b clinical data for rexaceract in Parkinson's disease, showing stable motor scores, no overall disease progression, and reductions in CSF GluSph levels, with the drug generally well tolerated and no new safety concerns.

Key details

RegistrantGain Therapeutics, Inc.
Chief executive officerGene Mack

How GANX stock reacted

Close before

$0.94

Nov 16, 2026

First close after

+24.97%

$1.18

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for GANX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for GANX?

Click here

Frequently asked questions

What did GANX file with the SEC on Nov 17, 2026?

GANX filed a 8-K (SEC filing). Gain Therapeutics announced positive 12-month Phase 1b clinical data for rexaceract in Parkinson's disease, showing stable motor scores, no overall disease progression, and reductions in CSF GluSph levels, with the drug generally well tolerated and no new safety concerns.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did GANX stock react to this filing?

GANX closed at $0.94 before the filing and $1.18 on Nov 17, 2026 (+24.97%).

Other GANX SEC filings

Get alerts when GANX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days